Predictors of Time to Metastasis in Castration-resistant Prostate Cancer.

ABSTRACT: To investigate predictors of time to metastasis among men treated with androgen deprivation therapy for nonmetastatic prostate cancer who developed castration-resistant prostate cancer (CRPC) within the Shared Equal Access Regional Cancer Hospital cohort.This is a retrospective analysis of 458 nonmetastatic CRPC men. Metastases were detected in routine bone scans or other imaging tests. Predictors of time to metastasis were analyzed using proportional hazards model with CRPC as time zero.A total of 256 (56%) men were diagnosed with metastatic disease over a median follow-up of 36 months. Metastasis-free survival was 79%, 65%, 52%, 47%, and 41% at 1, 2, 3, 4, and 5 years after CRPC, respectively. In multivariable analysis, Gleason score 8-10 (hazard ratio [HR]?=?1.61; P?=?.026), receiving primary localized treatment (HR?=?1.38; P?=?.028), higher prostate-specific antigen (PSA) levels at CRPC diagnosis (logPSA HR?=?1.64; P?

SUBMITTER: Moreira DM 

PROVIDER: S-EPMC5536963 | biostudies-literature | 2016 Oct

REPOSITORIES: biostudies-literature